Key Highlights
- Sean A. MacDonald appointed as CEO, previously Chief Business Officer and Executive Strategic Advisor at Domain Therapeutics.
- Will lead Domain’s Series B fundraising and expand its portfolio of GPCR-targeting cancer therapies.
- Has a strong background in business development and strategic planning across North America and Europe.
Source: Business Wire
Notable Quotes
- “2024 is set to be a pivotal year for the Company and I am honoured to have been given the opportunity to lead and support the tremendous talent at Domain.” – Sean A. MacDonald, CEO at Domain Therapeutics
- “Sean’s profound understanding of Domain and strategic and operational expertise…makes him ideal to be at the operative helm of the Company as CEO.” – Laurence Rulleau, Chair of the Board at Domain Therapeutics
SoHC's Take
The appointment of Sean A. MacDonald as CEO of Domain Therapeutics marks a significant milestone in the company’s journey towards becoming a leader in the field of immuno-oncology. MacDonald’s extensive experience in strategy and business development is well-suited to guide Domain through its next growth phase, particularly in advancing its innovative GPCR-targeting therapies. This strategic decision by the board reflects a clear vision for the company’s future, emphasizing robust leadership to enhance their clinical developments. MacDonald’s leadership style and track record suggest that Domain will continue to excel in creating impactful cancer treatments, benefiting patients globally.
